Imcivree (setmelanotide) is a protein pharmaceutical. Setmelanotide was first approved as Imcivree on 2020-11-25. It has been approved in Europe to treat obesity. It is known to target melanocortin receptor 4, melanocortin receptor 3, melanocyte-stimulating hormone receptor, and melanocortin receptor 5. Imcivree's patent is valid until 2027-10-13 (FDA).
|Drug Class||Peptides: melanocortin receptor antagonists|